These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 21728843)
1. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience. Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843 [TBL] [Abstract][Full Text] [Related]
3. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy. Das T; Banerjee S; Shinto A; Kamaleshwaran KK; Sarma HD Curr Radiopharm; 2014; 7(1):12-9. PubMed ID: 24934713 [TBL] [Abstract][Full Text] [Related]
4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
5. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[ Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891 [No Abstract] [Full Text] [Related]
6. The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [ van Andel L; Aalbersberg EA; Geluk-Jonker MM; Stokkel MPM; Beijnen JH; Hendrikx JJMA J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122605. PubMed ID: 33740691 [TBL] [Abstract][Full Text] [Related]
7. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor. Das T; Chakraborty S; Banerjee S; Venkatesh M Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119 [TBL] [Abstract][Full Text] [Related]
8. Design, preparation and biological evaluation of a Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215 [TBL] [Abstract][Full Text] [Related]
9. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT. Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369 [TBL] [Abstract][Full Text] [Related]
11. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728 [TBL] [Abstract][Full Text] [Related]
12. Response to Single Low-dose Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731 [No Abstract] [Full Text] [Related]
13. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254 [TBL] [Abstract][Full Text] [Related]
14. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290 [TBL] [Abstract][Full Text] [Related]
15. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Lewis JS; Wang M; Laforest R; Wang F; Erion JL; Bugaj JE; Srinivasan A; Anderson CJ Int J Cancer; 2001 Dec; 94(6):873-7. PubMed ID: 11745491 [TBL] [Abstract][Full Text] [Related]
16. Real-world comparison of healthcare resource utilization and costs of [ Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254 [TBL] [Abstract][Full Text] [Related]
17. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003 [TBL] [Abstract][Full Text] [Related]
18. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Hosono M; Ikebuchi H; Nakamura Y; Nakamura N; Yamada T; Yanagida S; Kitaoka A; Kojima K; Sugano H; Kinuya S; Inoue T; Hatazawa J Ann Nucl Med; 2018 Apr; 32(3):217-235. PubMed ID: 29333565 [TBL] [Abstract][Full Text] [Related]
19. Formulation of patient dose of ¹⁷⁷Lu-DOTA-TATE in hospital radiopharmacy in India: preparation using in situ methodology vis-a-vis freeze-dried kit. Das T; Banerjee S Cancer Biother Radiopharm; 2014 Sep; 29(7):301-2. PubMed ID: 25203147 [No Abstract] [Full Text] [Related]
20. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models. Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]